Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Implementing ALCOA+ for AAV Vector Analytics

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Implementing ALCOA+ for AAV Vector Analytics

CELL & GENE | RNA | BIOLOGICS

A stylized rendering of a DNA double helix on the left side of a light blue gradient background.

Proven Intelligence in AAV Vector Analytics.

Executive Summary

For AAV programs targeting global regulatory submissions, data integrity is the foundation of a successful IND application. Implementing ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available) within the analytical framework is a foundational component of a successful regulatory strategy. This approach ensures that all characterization, potency, and purity data generated for an AAV vector is irrefutable, traceable, and compliant with harmonized international guidelines (ICH), directly supporting accelerated 18-24 month IND timelines.

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

Frequently Asked Questions

What is ALCOA+ and why is it relevant for AAV vector analytics?

ALCOA+ is a data integrity framework mandated by global regulatory bodies. For AAV analytics, it ensures that all data generated – from vector titer and purity to potency assays – is Attributable, Legible, Contemporaneous, Original, and Accurate. The “+” adds Complete, Consistent, Enduring, and Available. This framework is foundational for building a defensible data package for IND-enabling toxicology studies and multi-jurisdictional submissions to agencies like the FDA and MHRA.

How does robust data integrity impact IND submissions for next-generation therapies?

For complex next-generation therapeutics, regulators scrutinize the analytical data package with extreme diligence. A data set built on ALCOA+ principles provides a clear, auditable trail that substantiates product quality and consistency claims. This minimizes regulatory questions, reduces the risk of clinical holds, and directly supports the 100% successful IND rate our core scientific team has maintained since 2019, even as Franklin Biolabs formally launched in 2024.

Can a CRO’s analytical process accommodate novel or engineered AAV capsids?

Yes. A principled analytical strategy is vector-agnostic. Whether characterizing a well-established serotype like AAV9 or a novel engineered capsid, the data integrity standards remain the same. The ALCOA+ framework provides the necessary structure to validate custom assays and generate reliable data for any AAV vector, ensuring the analytical methods are fit-for-purpose and the results are defensible.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

AAV Analytics: Beyond Data Generation to Data Integrity

In the development of AAV-based next-generation therapeutics, the analytical data package serves as the definitive record of product quality. For sponsors targeting global markets, this data must be universally understood and accepted by multiple regulatory bodies. Adherence to ALCOA+ principles provides this universal standard, transforming raw analytical outputs into a coherent, defensible narrative for IND and IMPD submissions.

The framework ensures every data point meets stringent criteria:

  • Attributable: Who performed an action and when?

  • Legible: Can the data be read and understood throughout its lifecycle?

  • Contemporaneous: Is information recorded at the time of the activity?

  • Original: Is the data the first recording or a certified true copy?

  • Accurate: Are the results free from error and reflective of the observation?

The “+” attributes – Complete, Consistent, Enduring, and Available – further reinforce the data package, ensuring no information is lost and that it remains accessible for audits and inspections for its entire lifecycle.

Substantiating Vector Performance with Defensible Data

The strategic value of ALCOA+ becomes clear when substantiating the selection of a specific AAV serotype for a given therapeutic application. For instance, preclinical studies may demonstrate the superior cardiac transduction efficiency of an AAV9 vector (PMID: 18795839) or its utility in reconstituting functional human T-cells in specialized preclinical models (PMID: 24516613). The analytical data supporting these functional claims : from vector genome titer to capsid protein purity : must be unimpeachable. ALCOA+ provides the framework to ensure this data withstands the highest levels of regulatory scrutiny.

This rigorous approach to data management is a core component of a successful vector development program. For a deeper look at the foundational elements of AAV projects, from capsid selection to manufacturing scalability, our scientific leadership explores these topics in detail.

Applying this level of analytical rigor requires deep, domain-specific expertise in all aspects of vector production and characterization.

This continuity of expertise ensures that the same rigorous standards that supported past programs are applied to current and future AAV vector analytics, providing a stable foundation for sponsors. Our approach is designed to produce a single, cohesive data package that supports global filings, aligning with ICH guidelines to streamline the path to clinical trials.

For more information on our comprehensive analytical capabilities, please see our parent hub page on Vector | CMC | Analytics Services.

Visualizing the ALCOA+ Framework for AAV Analytics

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities